About: covid:PMC7289615

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7289615 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Hoff, Paulo Aguiar, Samuel Andrade, Aline Carvalho, Elisângela Coimbra, Felipe Coutinho, Anelisa Crosara, Marcela Fernandes, Gustavo Filho, Duílio Gansl, Rene Peixoto, Renata Prolla, Gabriel Rego, Juliana Riechelmann, Rachel Weschenfelder, Rui
is schema:about of	named entity 'Evidence-based' named entity 'gastrointestinal cancers' named entity 'high-risk' named entity 'Bayer' named entity 'Novartis' named entity '250,000' named entity 'metastatic disease' named entity 'capecitabine' named entity 'somatostatin' named entity 'Liver transplantation' named entity 'PET-CT' named entity 'Novartis' named entity 'COVID-19' named entity 'Sanofi' named entity 'metastatic spread' named entity 'refractory' named entity 'Resectable' named entity 'NEC' named entity 'intravenous' named entity 'COVID-19' named entity 'HER2' named entity 'midgut' named entity 'metastases' named entity 'Bayer' named entity 'Novartis' named entity 'cardiovascular' named entity 'tested for COVID-19' named entity 'metastatic disease' named entity 'monoclonal antibodies' named entity 'bile duct' named entity 'gastrointestinal' named entity 'diabetes mellitus' named entity 'capecitabine' named entity 'Amgen' named entity 'Roche' named entity 'chemotherapy regimens' named entity 'regorafenib' named entity 'somatostatin' named entity 'SARS-CoV-2' named entity 'peptide' named entity 'tumour' named entity 'NETs' named entity 'everolimus' named entity 'Roche' named entity 'monoclonal antibodies' named entity 'immunotherapy' named entity 'elective surgery' named entity 'nonprofit organisation' named entity 'tumour' named entity 'MDT' named entity 'esophagus' named entity 'oncological' named entity 'lymph-node' named entity 'cisplatin' named entity 'liver' named entity 'meta-analyses' named entity 'SARS CoV2' named entity 'PET-CT' named entity 'adenocarcinomas' named entity 'oncology' named entity 'chemotherapy' named entity 'Merck' named entity 'surgical procedures' named entity 'cisplatin' named entity 'octreoscan' named entity 'second-line therapy' named entity 'COVID' named entity 'ECOG' named entity 'temozolamide' named entity 'colon' named entity 'Amgen' named entity 'liver function' named entity 'Resectable' named entity 'chemotherapy' named entity 'carcinoid syndrome' named entity 'performance status' named entity 'Amgen' named entity 'Ipsen' named entity 'adjuvant' named entity 'Metastatic' named entity 'Coronavirus disease 2019' named entity 'immunosuppressive' named entity 'capecitabine' named entity 'cetuximab' named entity 'neuroendocrine'

Attributes

Values

Creator

Hoff, Paulo
Aguiar, Samuel
Andrade, Aline
Carvalho, Elisângela
Coimbra, Felipe
Coutinho, Anelisa
Crosara, Marcela
Fernandes, Gustavo
Filho, Duílio
Gansl, Rene
Peixoto, Renata
Prolla, Gabriel
Rego, Juliana
Riechelmann, Rachel
Weschenfelder, Rui

is schema:about of

named entity 'Evidence-based'
named entity 'gastrointestinal cancers'
named entity 'high-risk'
named entity 'Bayer'
named entity 'Novartis'
named entity '250,000'
named entity 'metastatic disease'
named entity 'capecitabine'
named entity 'somatostatin'
named entity 'Liver transplantation'
named entity 'PET-CT'
named entity 'Novartis'
named entity 'COVID-19'
named entity 'Sanofi'
named entity 'metastatic spread'
named entity 'refractory'
named entity 'Resectable'
named entity 'NEC'
named entity 'intravenous'
named entity 'COVID-19'
named entity 'HER2'
named entity 'midgut'
named entity 'metastases'
named entity 'Bayer'
named entity 'Novartis'
named entity 'cardiovascular'
named entity 'tested for COVID-19'
named entity 'metastatic disease'
named entity 'monoclonal antibodies'
named entity 'bile duct'
named entity 'gastrointestinal'
named entity 'diabetes mellitus'
named entity 'capecitabine'
named entity 'Amgen'
named entity 'Roche'
named entity 'chemotherapy regimens'
named entity 'regorafenib'
named entity 'somatostatin'
named entity 'SARS-CoV-2'
named entity 'peptide'
named entity 'tumour'
named entity 'NETs'
named entity 'everolimus'
named entity 'Roche'
named entity 'monoclonal antibodies'
named entity 'immunotherapy'
named entity 'elective surgery'
named entity 'nonprofit organisation'
named entity 'tumour'
named entity 'MDT'
named entity 'esophagus'
named entity 'oncological'
named entity 'lymph-node'
named entity 'cisplatin'
named entity 'liver'
named entity 'meta-analyses'
named entity 'SARS CoV2'
named entity 'PET-CT'
named entity 'adenocarcinomas'
named entity 'oncology'
named entity 'chemotherapy'
named entity 'Merck'
named entity 'surgical procedures'
named entity 'cisplatin'
named entity 'octreoscan'
named entity 'second-line therapy'
named entity 'COVID'
named entity 'ECOG'
named entity 'temozolamide'
named entity 'colon'
named entity 'Amgen'
named entity 'liver function'
named entity 'Resectable'
named entity 'chemotherapy'
named entity 'carcinoid syndrome'
named entity 'performance status'
named entity 'Amgen'
named entity 'Ipsen'
named entity 'adjuvant'
named entity 'Metastatic'
named entity 'Coronavirus disease 2019'
named entity 'immunosuppressive'
named entity 'capecitabine'
named entity 'cetuximab'
named entity 'neuroendocrine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software